The Five Questions My Patients Are Now Asking About PMOS

And the five metabolic interventions I give them in response — the answers medicine should have been delivering for twenty years.

THE METABOLIC FIX

Founder & CEO, ProvationLife™ | Host, The Metabolic Fix | Board-Certified OB/GYN

25 Years Clinical Practice in Women’s Metabolic Health

Introduction

Something shifted in my exam room this week.

Women who have been my patients for years — women who have been living with PCOS for a decade or more — are coming in differently. They’ve read the Lancet article. They’ve seen the discussion online. They know that a serious proposal to rename their condition has been gaining scientific momentum, and they want to understand what it means for them.

The new name is PMOS: Polycystic Metabolic-Ovarian Syndrome. The addition of a single word — Metabolic — may seem like academic housekeeping. It is not. It is a paradigm correction that has been needed for thirty years, and the questions my patients are asking in response to it reveal exactly how much damage the old framing caused.

Below I’ve organized the five most common questions I’m now fielding in clinical practice around this name change. But I’m not stopping at the questions. For each one, I’m giving you the metabolic intervention that actually follows from the answer — because the purpose of renaming this condition is not semantic satisfaction. It is clinical action.

If you have PCOS — PMOS — and from this point forward I will use both terms interchangeably — this is the reframe your care has been waiting for.

PART ONE

The Five Questions

01 THE DIAGNOSIS QUESTION

“Does this mean my diagnosis is wrong?”

The first thing I hear when a patient learns about PMOS is some version of panic. Years of living with PCOS — the labs, the medications, the grief — and now I’m telling her the name has changed. The look on her face says: did someone get this wrong?

Your diagnosis was never wrong. PCOS was always real. What changed is our understanding of what was driving it — and that changes everything about how we treat it.

Polycystic Metabolic-Ovarian Syndrome. That’s what PMOS stands for. The Metabolic is the new word, and it is the most important word that has ever been inserted into this diagnosis. Because here is what 25 years of clinical practice has taught me: the cysts were never the disease. They were the symptom of a disease we were describing backwards.

The old name — Polycystic Ovary Syndrome — pointed the finger at the ovary. So generations of women were told their ovaries were the problem. The irregular cycles, the androgen excess, the infertility — all ovarian pathology. The metabolic dysfunction underneath it? Background noise. Weight management advice. Lifestyle recommendations buried on page three of the visit summary.

PMOS does not change what happened to you. It changes what we do next. And what we do next is treat the root — which is metabolic.

“The cysts were never the disease. They were a downstream signal of a metabolic system that had been dysregulated, often for years, before a single follicle became visible on ultrasound.”

— Herman Weiss, MD, MBA, FACOG

02 THE WEIGHT QUESTION

“Why has no one ever told me that weight loss is supposed to be this hard?”

This question does not come with curiosity. It comes with years of accumulated shame. The calorie counting. The diets. The workouts. The doctor who said ‘just lose five percent of your body weight’ like it was a matter of willpower. I hear this and I feel the weight of what medicine failed to explain.

It is harder. Measurably, biochemically, mechanistically harder. And you were told it wasn’t, which is one of the most damaging things we have done to women with this condition.

Here is the mechanism. PMOS is, at its core, a hyperinsulinemic state. Insulin is elevated — often significantly elevated — even in women whose fasting glucose looks perfectly normal. And insulin is the master fat-storage hormone. When insulin is chronically elevated, your adipose tissue receives a continuous biochemical signal to store, not release, energy. You are working against your own hormonal environment every time you try to create a caloric deficit.

Add to this: elevated androgens suppress adiponectin, an anti-inflammatory adipokine that promotes fat oxidation. Leptin resistance — common in PMOS — blunts satiety signaling so hunger is amplified. And cortisol dysregulation, which is endemic in this condition, preferentially deposits visceral fat regardless of total caloric intake.

You were not failing. You were fighting a biochemical tide while being told the water was calm. PMOS names that tide. And naming it means we can finally work with it instead of pretending it doesn’t exist.

“When insulin is chronically elevated, your body receives a continuous signal to store energy, not release it. Willpower cannot override a hormonal instruction written in the language of your own metabolism.”

— Herman Weiss, MD, MBA, FACOG

03 THE FERTILITY QUESTION

“Does PMOS change anything about my ability to get pregnant?”

This one lands differently depending on where a woman is in her journey. For some it’s urgent — she’s been trying for two years. For others it’s future-facing, still theoretical. But it is always present, always weighed.

The biology of anovulation in this condition has not changed. What has changed is our ability to address the root cause rather than just the downstream symptom.

In PMOS, the most common driver of anovulation is hyperinsulinemia. Elevated insulin stimulates ovarian theca cells to produce excess androgens, which disrupts follicular maturation and prevents ovulation. We have been treating this with ovulation induction agents — clomiphene, letrozole — which work on the symptom. PMOS now frames insulin as the primary target.

What this means practically: metabolic optimization should come before, not after, ovulation induction. Insulin sensitization — whether through diet, exercise, inositol, metformin, or some combination — can restore ovulatory function in a meaningful percentage of women before we ever write an ovulation induction prescription.

The PMOS framework does not eliminate the need for reproductive intervention. It changes the sequence. And in that sequence, many women may find they need far less intervention than they expected.

“Metabolic optimization is not the consolation prize before fertility treatment. In PMOS, it is often the fertility treatment — and it is the one we have been systematically deprioritizing.”

— Herman Weiss, MD, MBA, FACOG

04 THE PERIMENOPAUSE QUESTION

“I am in my mid-forties — is this the same thing returning?”

This question is being asked by a growing cohort of women diagnosed in their twenties, managed symptomatically for two decades, now watching symptoms return with new intensity — anxiety, brain fog, weight that won’t move, unpredictable cycles. They’re right to wonder if this is connected.

It is connected. And the connection is metabolic.

Perimenopause and PMOS both involve hormonal flux but converge on a shared metabolic substrate. As estrogen declines in perimenopause, insulin sensitivity decreases — a direct, well-documented effect of estrogen withdrawal on peripheral glucose disposal. For a woman who has been living with subclinical insulin resistance for twenty years, this additional metabolic stress can unmask or amplify symptoms that had been partially controlled.

The brain fog, the mood instability, the sleep disruption, the visceral weight gain — these are not purely estrogenic symptoms. They are metabolic symptoms. And in the woman with longstanding PMOS entering perimenopause, the two systems are dysregulating simultaneously.

This matters because treatment cannot be purely hormonal. Adding estrogen may help. But if the underlying insulin resistance is not addressed, the metabolic cascade continues underneath the hormonal intervention. We are managing two overlapping metabolic transitions. Both must be treated.

“When a woman with PMOS enters perimenopause, two metabolic systems begin to destabilize simultaneously. The approach that treats only one of them will leave the other unaddressed — and she will feel it.”

— Herman Weiss, MD, MBA, FACOG

05 THE MEDICATION QUESTION

“I have been on the pill for twelve years to manage my PCOS. Was that actually treating anything?”

I take a breath before answering this one, because the honest answer is complicated. The oral contraceptive pill is one of the most prescribed interventions in the history of PCOS management. PMOS reframes what treatment actually means.

The pill managed symptoms. It did not treat the underlying condition. And for many women, that distinction has been blurred for a decade or more.

Oral contraceptives suppress ovarian androgen production and provide cycle regularity. Those are real clinical benefits. But here is what the pill cannot do: it cannot improve insulin sensitivity. In fact, certain formulations can worsen it. It cannot address the gut microbiome dysregulation that drives the estrobolome disruption common in PMOS. It cannot reduce chronic systemic inflammation.

So for twelve years, the symptom was managed and the disease progressed. The PMOS framework asks us to return to that foundational question: what is the metabolic state of this patient, and what would it take to actually change it?

That is not an accusation against the physicians who prescribed the pill. It is an honest reckoning with what we defined as treatment — and what we should have been asking all along.

“The pill regulated the cycle. It did not regulate the metabolism. For millions of women, those twelve years of management were twelve years of downstream symptom suppression while the root cause ran uncontested.”

— Herman Weiss, MD, MBA, FACOG

PART TWO

The Five Recommendations

The name change is not the intervention. This is.